患有STEMI的糖尿病患者接受PCI的埃沃洛库马布的临床益处:一项回顾性研究
1Cardiovascular Department, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, P. R. China.
埃沃洛库马布显著有利于患有ST段升高心肌梗塞 (STEMI) 的糖尿病患者,这些患者正在接受皮肤冠状动脉干预 (PCI). 这种治疗减少了心血管事件,改善了脂质水平,但没有增加不良反应.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 经过皮肤冠状动脉干预 (PCI) 的ST段升高心肌梗塞 (STEMI) 糖尿病患者往往面临更高的风险.
- 埃沃洛库马布在中国这一特定高风险人群中的临床益处此前尚不清楚.
研究的目的:
- 评估evolocumab在接受PCI的STEMI的中国糖尿病患者中的安全性和有效性.
- 评估evolcumab对血脂水平,LVEF和不良事件的影响.
主要方法:
- 在184名患有STEMI的糖尿病患者进行PCI后期研究.
- 患者被分为evolocumab和对照组.
- 评估初级疗效终点,血脂和6个月和12个月的不良事件.
主要成果:
- 埃沃洛库马布显著降低了血脂水平和内部介质厚度,同时增加了LVEF.
- 在evolocumab组观察到初级疗效终点的显著降低.
- 两组之间的不良反应没有显著差异;预后模型将evolocumab确定为保护性.
结论:
- 埃沃洛库马布在接受PCI的STEMI糖尿病患者中显示出显著的临床益处.
- 这些发现支持考虑evolocumab以减轻该患者队列未来心血管事件风险.
更多相关视频
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
相关概念视频
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
